Oncogenic and Therapeutic Targeting of PTEN Loss in Bone Malignancies

Journal of Cellular Biochemistry
Yongming Xi, Yan Chen

Abstract

Being a tumor suppressor, PTEN functions as a dual-specificity protein and phospholipid phosphatase and regulates a variety of cellular processes and signal transduction pathways. Loss of PTEN function has been detected frequently in different forms of cancers, such as breast, prostate and lung cancer, gastric and colon cancer, skin cancer, as well as endometrial carcinoma. In this review, we provide a summary of PTEN and its role in bone malignancies including bone metastases, multiple myeloma, and osteosarcoma, etc. We highlight the importance of PTEN loss leading to activation of the oncogenic PI3K/Akt/mTOR pathway in tumorigenesis and progression, which can be attributed to both genetic and non-genetic alterations involving gene mutation, loss of heterozygosity, promoter hypermethylation, and microRNA mediated negative regulation. We also discuss the emerging therapeutic applications targeting PTEN loss for the treatment of these bone malignant diseases.

References

Jun 1, 1996·Genes, Chromosomes & Cancer·W H RaskindM Matsushita
Nov 5, 1999·Journal of the National Cancer Institute·M TamuraK M Yamada
Nov 24, 1999·Journal of the National Cancer Institute·I U AliM Dean
Feb 29, 2000·Cell·A Di Cristofano, P P Pandolfi
Feb 21, 2002·Diagnostic Molecular Pathology : the American Journal of Surgical Pathology, Part B·Chuzhao LinRichard M Terek
May 17, 2002·Veterinary Pathology·R A LevineC Smith
Jun 1, 2002·Science·Lewis C Cantley
Jun 28, 2002·Cancer Metastasis Reviews·E T KellerR S Taichman
Aug 3, 2002·Nature Reviews. Cancer·Gregory R Mundy
Dec 4, 2002·The Journal of Biological Chemistry·Toshifumi SugataniKeith A Hruska
May 23, 2003·Journal of Cellular Biochemistry·Yan-Xi SunRussell S Taichman
Aug 15, 2003·Molecular and Cellular Biology·Aurelian RaduMaria-Magdalena Georgescu
Oct 31, 2003·Cancer Cell·Ji LuoLewis C Cantley
Jan 5, 2005·Nature Reviews. Cancer·Christopher J Logothetis, Sue-Hwa Lin
May 3, 2005·Nature Reviews. Cancer·Nancy E Hynes, Heidi A Lane
Jul 19, 2006·Nature Reviews. Genetics·Jeffrey A EngelmanLewis C Cantley
Feb 5, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Alissa HustonIrene M Ghobrial
Aug 8, 2008·Current Opinion in Supportive and Palliative Care·William C Dougall
Sep 5, 2008·Annual Review of Pathology·Nader Chalhoub, Suzanne J Baker
Oct 16, 2008·British Journal of Cancer·P McCallJ Edwards
Apr 20, 2010·Nature Genetics·Andrea AlimontiPier Paolo Pandolfi
Jun 29, 2010·International Journal of Hematology·Suyun WangLing Pan
Oct 12, 2010·The Journal of International Medical Research·J-J XiaJ-L Yan
Apr 15, 2011·Molecular Cancer Therapeutics·Ana M Gonzalez-AnguloFunda Meric-Bernstam
May 11, 2011·Nature Reviews. Clinical Oncology·Justin SturgeJonathan Waxman
May 28, 2011·International Journal of Oncology·Shinji MiwaHiroyuki Tsuchiya
Jul 23, 2011·Genes & Cancer·Maria-Magdalena Georgescu
Nov 22, 2011·Pediatric Blood & Cancer·Richard GorlickMalcolm A Smith
Dec 2, 2011·The Journal of Immunology : Official Journal of the American Association of Immunologists·Jang Bae MoonNacksung Kim

❮ Previous
Next ❯

Citations

Sep 18, 2015·Frontiers in Pediatrics·Valerie B SampsonE Anders Kolb
Sep 22, 2016·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Li ChengGuanzhen Yu
Jan 21, 2017·Journal of Cellular Biochemistry·Yongming Xi, Yan Chen
Apr 24, 2018·Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals·Jiangli LangXijie Yu
Jun 30, 2019·Journal of Medical Case Reports·Mickaël BurgyRoland Schott
Apr 6, 2021·Journal of Orthopaedic Science : Official Journal of the Japanese Orthopaedic Association·Bingyi TanJun Dong

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.